Skip to content

13F-HR filed by Casdin Capital, LLC

Casdin Capital, LLC filed this 13F-HR for the quarter ended 2019-03-31, filed 2019-05-15, with 29 holding rows worth $910,374,000.

Accession
0001534261-19-000008
Filed
2019-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2019

A holdings report, 29 entries on the cover page, a total value of $910,374,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $910,374,000 with VALUE read as thousands by filing date, 13F file number 028-17113. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPARK THERAPEUTICS INC84652J103COM940,000$107,047,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM848,648$67,934,000thousands by filing date
MYOKARDIA INC62857M105COM1,285,000$66,807,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM400,000$63,620,000thousands by filing date
BLUEBIRD BIO INC09609G100COM357,500$56,245,000thousands by filing date
INVITAE CORP46185L103COM2,200,000$51,524,000thousands by filing date
FATE THERAPEUTICS INC31189P102COM2,550,000$44,804,000thousands by filing date
DIANTHUS THERAPEUTICS INC COM55910K108Stock2,643,318$43,535,000thousands by filing date
BIOLIFE SOLUTIONS INC COM NEW09062W204Stock2,428,571$43,447,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock445,000$41,585,000thousands by filing date
CODEXIS INC192005106COM2,025,000$41,573,000thousands by filing date
AUDENTES THERAPEUTICS INC.05070R104Common Stock1,010,000$39,410,000thousands by filing date
SAREPTA THERAPEUTICS INC803607100COM305,000$36,353,000thousands by filing date
GENMARK DIAGNOSTICS INC372309104COM3,365,000$23,858,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM335,000$22,592,000thousands by filing date
VOYAGER THERAPEUTICS INC92915B106COMMON STOCK1,128,075$21,591,000thousands by filing date
CONSTELLATION PHARMACEUTICALS INC.210373106Common Stock1,556,999$21,097,000thousands by filing date
ILLUMINA INC452327109COM60,000$18,641,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM300,000$15,879,000thousands by filing date
GRITSTONE BIO INC39868T105COM1,120,586$14,904,000thousands by filing date
EDITAS MEDICINE INC28106W103COM480,000$11,736,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM1,080,000$10,303,000thousands by filing date
TRANSPORTATION & LOGISTI438083107COM350,000$9,706,000thousands by filing date
BEONE MEDICINES LTD SPONSORED ADS07725L102ADR70,000$9,240,000thousands by filing date
EVOLENT HEALTH INC CL A30050B101Stock550,000$6,919,000thousands by filing date
CAREDX INC14167L103COM200,000$6,304,000thousands by filing date
ALECTOR INC014442107COMMON STOCK331,039$6,197,000thousands by filing date
Gilead Sciences,Inc.375558103COM80,000$5,201,000thousands by filing date
DENALI THERAPEUTICS INC COM24823R105Stock100,000$2,322,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001534261-19-000008this filing2019-05-15acceptance time not in the bulk data set